Menarini Group reports new data from the Phase 3 SENTRY trial for the combination of selinexor and ruxolitinib in patients with myelofibrosis at the 2026 Congress of the European Hematology Association (EHA). The company says the combination meets the first co-primary endpoint, showing a statistically significant improvement in spleen volume reduction (SVR35) at week 24. According to the reported results, SVR35 is 49.8% in the selinexor plus ruxolitinib arm versus 28% in the control arm. Both releases describe this as an early demonstration of efficacy based on the trial’s primary measures. The company also states that additional post-hoc analyses are included in the presentation, though the supplied excerpts do not detail those analyses further. These updates are presented as part of Menarini’s congress disclosures and reflect outcomes from the ongoing Phase 3 study assessing the effectiveness of the drug combination compared with the control regimen.
Menarini presents Phase 3 SENTRY results for selinexor plus ruxolitinib in myelofibrosis
Menarini Group reports new data from the Phase 3 SENTRY trial for the combination of selinexor and ruxolitinib in patients with myelofibrosis at the 2026 Congress of the European Hematology Associatio...
- Menarini Group presents Phase 3 SENTRY trial data at the 2026 EHA Congress.
- The treatment studied is selinexor plus ruxolitinib for myelofibrosis.
- The combination meets the first co-primary endpoint based on spleen volume reduction.
- SVR35 at week 24 is reported as 49.8% for the combination arm versus 28% for the control arm.
- Menarini also includes additional post-hoc analyses in the presentation.
Die Kombination aus Selinexor und Ruxolitinib erreichte den ersten koprimären Endpunkt und zeigte in Woche 24 eine statistisch signifikante Verbesserung der Milzvolumenreduktion (SVR35) von 49,8 % in der Kombinationsgruppe gegenüber 28 % in der Kontrollgruppe. Eine Post-hoc-Analyse der...
2 hours agoThe combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. Post-hoc analysis from the phase 3 SENTRY trial...
8 hours ago
Trump urges restraint after Israel strikes Beirut amid US-Iran peace talks
US President Donald Trump calls for restraint after Israel launches fresh airstrikes on Beirut, urging all parties to “s...
Riverside suburbs transform from dumps and factories into affluent riverfront estates
Multiple outlets describe how a previously overlooked riverside area has changed markedly over time, replacing older ind...
Voters back One Nation and Pauline Hanson as preferred prime minister, poll shows
Multiple reports describe a shift in voter preferences that they say serves as a warning to Australia’s political mainst...